COOPER PHARMA and OSI sign distribution agreement to protect and prevent against respiratory viruses, including the one that causes COVID-19


BROSSARD, QC and Casablanca, Morocco, August 11, 2021 / CNW / – An innovative broad-spectrum natural organic barrier is needed to prevent viral respiratory infections. COOPER PHARMA and OSI have signed a distribution agreement to market Flavobac â„¢ Cold & Flu Guard â„¢. Under the terms of this agreement, OSI grants COOPER PHARMA the exclusive right to distribute Flavobac â„¢ Cold & Flu Guard â„¢ in Morocco and the United Arab Emirates (UNITED ARAB EMIRATES). COOPER PHARMA and its affiliates will use their sales, marketing and e-commerce expertise to distribute Flavobac â„¢ Cold & Flu Guard â„¢ once product registration has been obtained from Moroccan and UAE health authorities.

Flavobac â„¢ Cold & Flu Guard â„¢ will become an essential part of COOPER PHARMA’s medical solutions, to protect children, parents, healthcare professionals and society against respiratory viruses including SARS-CoV-2 which causes COVID- 19. “COOPER PHARMA is committed to helping reduce the impact of respiratory viral infections” declared Ayman Cheikh-Lahlou, the CEO of COOPER PHARMA.

Christian Sauvageau, President of OSI, said: “We are extremely proud of this opportunity to work with such a forward-thinking company as COOPER PHARMA. We have seen COOPER PHARMA’s total determination to bring innovative solutions to market and we are delighted to work with them. We also thank The Harel Group for identifying COOPER PHARMA as a strategic partner and for facilitating the entire transaction process, from the introduction to the execution of final agreements with COOPER PHARMA. “

Flavobac â„¢ Cold & Flu Guard â„¢ is a formulation based on a substance obtained from a natural source. It fights viruses by interfering with their ability to adhere to the oral and nasal mucosa. Flavobac â„¢ Cold & Flu Guard â„¢ has been shown to kill “99.8% of SARS-CoV-2 within 5 minutes as well as many other respiratory viruses such as human coronavirus, influenza virus, rhinovirus and VRS1. Flavobac â„¢ Cold & Flu Guard â„¢ is already registered in Europe, Canada and the United States. Efforts are underway to enable its use around the world. For more information, see

“COOPER PHARMA is proud to receive the distribution rights of Flavobac â„¢ Cold & Flu Guard â„¢ from our partner OSI in order to help people and healthcare professionals to protect themselves against respiratory viral infections, while respecting of course and above all the health recommendations in terms of prevention and treatment against respiratory viruses and in particular SARS-CoV-2 “declared Ayman Cheikh-Lahlou, the CEO of COOPER PHARMA. “An innovative broad-spectrum barrier to help reduce viral spread and viral loads is an important new option for protecting against respiratory viruses. Flavobac â„¢ Cold & Flu Guard â„¢ can neutralize viruses that have entered the nose and mouth and act as “local disinfectants” to destroy viruses before they have a chance to cause infection. Morocco, COOPER PHARMA is happy to provide people with a new tool to protect themselves against respiratory viruses, ”said Ayman Cheikh-Lahlou.

Since 1933, Cooper Pharma, a Moroccan pharmaceutical company, has supported health professionals in the service of a mission: to increase access to medicines for all. Cooper Pharma is today a leading laboratory in the national pharmaceutical industry, with its range of Cooper products, covering more than a hundred specialties and major therapeutic areas. Alongside its own products, Cooper Pharma is the partner of around twenty multinationals for which it represents around a hundred drugs, under license. Cooper Pharma is a producer, distributor and exporter of pharmaceutical specialties. Cooper Pharma is today a benchmark player in the Africa and Middle East region with commercial reach in Europe. Cooper Pharma has nine pharmaceutical factories that are wholly owned or in JV with local leaders on North Africa, West Africa, East Africa, the Gulf Cooperation Council countries and Europe. For more information, please visit:

About OSI
Oral Science International (OSI) is an innovation-driven company dedicated to the development and commercialization of innovative biotechnologies, providing solutions to oral / nasal infections and inflammation. Oral Science International has a strong and passionate management team committed to innovative oral care and infection control technologies that improve the quality of life for people of all ages. We are committed to customer-centric design and science-driven innovation. We are focused on providing safe, valuable and easy to use products for the global market. Our commitment to innovation, partnership and excellence rests on the foundation of a culture that greatly values ​​collaboration. We are guided by in-depth research that we share through publications and presentations, and in collaboration with all stakeholders.

About the Harel group
The Harel Group is a business development consultancy with in-depth industry knowledge and an extensive network of contacts in the pharmaceutical, biotechnology, diagnostics and medical devices sectors. The Harel Group supports clients looking to expand their global business footprint by identifying strategic partners and facilitating licensing and distribution agreements. For more information, please visit:

  • Efficacy of the bioflavonoid spray against respiratory viruses, Z Cheikh, H Lerner, Oral health, July 9, 2021
  • SOURCE Oral Science International


    Leave A Reply